<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND, MATERIALS AND METHODS: For the purpose of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> detection, we investigated fibrillin-2 (FBN2) methylation in the serum of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients using quantitative methylation-specific polymerase chain reaction (qMSP) </plain></SENT>
<SENT sid="1" pm="."><plain>RESULTS: Out of 78 patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, 49 (63%) exhibited methylation of FBN2 in their <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissue DNA, suggesting that FBN2 methylation frequently exists in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>We next examined the methylation status of FBN2 in the serum DNA of patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Out of 49 serum samples, four (8%) exhibited FBN2 methylation in their serum DNA by qMSP, suggesting that FBN2 methylation exists in the serum of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients </plain></SENT>
<SENT sid="4" pm="."><plain>After completion of qMSP analysis in <z:hpo ids='HP_0000001'>all</z:hpo> specimens, clinicopathological data were correlated with the molecular analysis findings </plain></SENT>
<SENT sid="5" pm="."><plain>Interestingly, methylation of FBN2 was found in the serum DNA of male (p=0.0167) patients, and in those with <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">hepatic metastasis</z:e> (p&lt;0.0001) </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: The clinical sensitivity of this assay can be potentially improved by incorporating other common genetic targets such as p53 and KRAS </plain></SENT>
<SENT sid="7" pm="."><plain>Advances in technology which will permit for rapid detection of an array of specific mutations and methylation would enhance the utility of this approach </plain></SENT>
</text></document>